75. Cushing disease
[
77 clinical trials,
106 drugs（DrugBank:
41 drugs),
33 target genes / 105 target pathways ]
Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03708900 | October 31, 2019 | 4 November 2019 | Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease | A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease | Cushing's Disease | Drug: LCI699 | Novartis Pharmaceuticals | Recruiting | 6 Years | 18 Years | All | 12 | Phase 2 | Bulgaria;United Kingdom | |
| 2 | NCT03974789 | July 1, 2019 | 26 August 2019 | Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms | Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms: Phase III Diagnostic Evaluation Study | Cushing Disease | Diagnostic Test: Blood test;Diagnostic Test: 24-hour Urine test;Diagnostic Test: Saliva swab;Diagnostic Test: Dexamethasone test | Centre Hospitalier Universitaire de Nimes | Recruiting | 18 Years | 65 Years | All | 380 | Phase 1 | France | |
| 3 | EUCTR2017-004647-20-ES | 17/01/2019 | 28 February 2019 | A Study to Assess Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome | An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome | Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: levoketoconazole Product Code: COR-003 Pharmaceutical Form: Tablet INN or Proposed INN: levoketozonazole CAS Number: 142128-57-2 Current Sponsor code: COR-003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | Cortendo AB | Authorised | Female: yes Male: yes | 60 | Phase 3 | United States;Greece;Spain;Turkey;Israel;Italy;France;Hungary;Poland;Romania;Denmark;Bulgaria;Netherlands | |||
| 4 | NCT03621280 | January 7, 2019 | 22 October 2019 | Open-label Treatment in Cushing's Syndrome | An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome | Cushing Syndrome;Cushing Disease | Drug: Levoketoconazole | Cortendo AB | Recruiting | 18 Years | N/A | All | 60 | Phase 3 | United States;Bulgaria;France;Greece;Hungary;Israel;Italy;Netherlands;Poland;Romania;Spain;Denmark;Turkey | |
| 5 | EUCTR2017-004647-20-HU | 13/11/2018 | 19 November 2018 | A Study to Assess Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome | An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome | Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: levoketoconazole Product Code: COR-003 Pharmaceutical Form: Tablet INN or Proposed INN: levoketozonazole CAS Number: 142128-57-2 Current Sponsor code: COR-003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | Cortendo AB | Authorised | Female: yes Male: yes | 60 | Phase 3 | Hungary;Poland;Romania;United States;Greece;Spain;Turkey;Israel;Italy;France;Denmark;Bulgaria;Netherlands | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03774446 | November 2, 2018 | 18 December 2018 | Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease | A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease | Cushing Disease | Drug: Seliciclib | Cedars-Sinai Medical Center | Recruiting | 18 Years | N/A | All | 29 | Phase 2 | United States | |
| 7 | EUCTR2017-002840-34-ES | 31/10/2018 | 7 January 2019 | Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat study | An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat | Cushing's syndrome MedDRA version: 20.0 Level: PT Classification code 10011652 Term: Cushing's syndrome System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: osilodrostat 1mg Product Code: LCI699 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: osilodrostat Current Sponsor code: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Product Name: osilodrostat 5mg Product Code: LCI699 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: osilodrostat Current Sponsor code: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Product Name: osilodrostat 10mg Product Code: LCI699 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: osilodrostat Current Sponsor code: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | Novartis Farmacéutica, S.A | Authorised | Female: yes Male: yes | 200 | Phase 2 | United States;Portugal;Greece;Thailand;Spain;Costa Rica;Russian Federation;Colombia;Switzerland;Italy;India;France;Netherlands;China;Korea, Republic of;Turkey;Austria;United Kingdom;Canada;Argentina;Brazil;Belgium;Poland;Bulgaria;Germany;Japan | |||
| 8 | NCT03697109 | October 16, 2018 | 30 September 2019 | A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome | Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant | Cushing Syndrome | Drug: Relacorilant;Other: Placebo | Corcept Therapeutics | Recruiting | 18 Years | 80 Years | All | 130 | Phase 3 | United States;Bulgaria;Israel;Italy;Netherlands;Poland;Spain | |
| 9 | EUCTR2017-002840-34-AT | 03/08/2018 | 10 September 2018 | Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat study | An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat | Cushing's syndrome MedDRA version: 20.0 Level: PT Classification code 10011652 Term: Cushing's syndrome System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: osilodrostat 1mg Product Code: LCI699 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: osilodrostat Current Sponsor code: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Product Name: osilodrostat 5mg Product Code: LCI699 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: osilodrostat Current Sponsor code: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Product Name: osilodrostat 10mg Product Code: LCI699 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: osilodrostat Current Sponsor code: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | Novartis Pharma AG | Authorised | Female: yes Male: yes | 200 | Phase 2 | United States;Portugal;Greece;Thailand;Spain;Costa Rica;Russian Federation;Colombia;Switzerland;Italy;India;France;Netherlands;China;Korea, Republic of;Turkey;Austria;United Kingdom;Canada;Argentina;Brazil;Belgium;Poland;Bulgaria;Germany;Japan | |||
| 10 | EUCTR2018-001616-30-HU | 09/07/2018 | 23 July 2018 | Extension of a clinical trial to assess the safety of a study drug called CORT125134 in the treatment of Cushing Syndrome | An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome | Endogenous Cushing Syndrome MedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860 ;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Code: CORT125134 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Relacorilant CAS Number: 1496510-51-0 Current Sponsor code: CORT125134 Other descriptive name: (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- | Corcept Therapeutics Incorporated | Authorised | Female: yes Male: yes | 75 | Phase 2 | United States;Hungary;Italy | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2017-001219-35-NL | 24/05/2018 | 28 February 2019 | A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome | A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome | Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860 ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Product Name: levoketoconazole Product Code: COR-003 Pharmaceutical Form: Tablet INN or Proposed INN: levoketozonazole CAS Number: 142128-57-2 Current Sponsor code: COR-003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Cortendo AB | Authorised | Female: yes Male: yes | 54 | Phase 3 | France;United States;Hungary;Greece;Poland;Spain;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy | |||
| 12 | JPRN-jRCTs021180039 | 24/05/2018 | 10 September 2019 | The usefulness of DDAVP test and GHRP-2 test in patients with Cushing's disease | The usefulness of DDAVP test and GHRP-2 test in patients with Cushing's disease - Cushing_diagnosis | Cushing's disease | administration of DDAVP or GHRP-2 | Kazunori Kageyama | Recruiting | 15age | Not applicated | Both | 15 | Phase 3 | none | |
| 13 | NCT03604198 | May 7, 2018 | 20 August 2018 | Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome | Cushing Syndrome | Drug: relacorilant | Corcept Therapeutics | Recruiting | N/A | N/A | All | 75 | Phase 2 | United States | |
| 14 | EUCTR2017-001219-35-BG | 23/01/2018 | 30 April 2019 | A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome | A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome | Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860 ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Product Name: levoketoconazole Product Code: COR-003 Pharmaceutical Form: Tablet INN or Proposed INN: levoketozonazole CAS Number: 142128-57-2 Current Sponsor code: COR-003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Cortendo AB | Authorised | Female: yes Male: yes | 54 | Phase 3 | France;United States;Hungary;Greece;Poland;Spain;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy | |||
| 15 | EUCTR2017-001219-35-ES | 22/01/2018 | 29 January 2018 | A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome | A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome | Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860 ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Product Name: levoketoconazole Product Code: COR-003 Pharmaceutical Form: Tablet INN or Proposed INN: levoketozonazole CAS Number: 142128-57-2 Current Sponsor code: COR-003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Cortendo AB | Authorised | Female: yes Male: yes | 40 | Phase 3 | United States;Greece;Spain;Israel;Italy;France;Hungary;Canada;Poland;Romania;Denmark;Bulgaria;Netherlands | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2017-001219-35-PL | 16/01/2018 | 28 February 2019 | A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome | A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome | Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860 ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Product Name: levoketoconazole Product Code: COR-003 Pharmaceutical Form: Tablet INN or Proposed INN: levoketozonazole CAS Number: 142128-57-2 Current Sponsor code: COR-003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Cortendo AB | Authorised | Female: yes Male: yes | 35 | Phase 3 | France;United States;Hungary;Greece;Spain;Poland;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy | |||
| 17 | EUCTR2017-001219-35-HU | 12/01/2018 | 22 January 2018 | A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome | A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome | Endogenous Cushing´s syndrome (CS) MedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860 ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Product Name: levoketoconazole Product Code: COR-003 Pharmaceutical Form: Tablet INN or Proposed INN: levoketozonazole CAS Number: 142128-57-2 Current Sponsor code: COR-003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Cortendo AB | Authorised | Female: yes Male: yes | 35 | Phase 3 | France;United States;Hungary;Greece;Poland;Spain;Romania;Denmark;Israel;Bulgaria;Netherlands;Italy | |||
| 18 | NCT03346954 | December 1, 2017 | 16 December 2017 | Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease | Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease | Cushing's Disease | Other: [11C]-Methionine PET/MRI | Hospices Civils de Lyon | Not recruiting | 18 Years | N/A | All | 30 | N/A | France | |
| 19 | NCT03277690 | September 26, 2017 | 22 July 2019 | A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome. | A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome | Endogenous Cushing's Syndrome | Drug: Levoketoconazole;Drug: Placebo | Cortendo AB | Recruiting | 18 Years | N/A | All | 54 | Phase 3 | United States;Spain;Romania;Poland;Netherlands;Italy;Israel;Hungary;Greece;France;Denmark;Bulgaria | |
| 20 | ChiCTR-OPC-17011664 | 2017-08-01 | 19 June 2017 | A single center clinical study of EGFR/HER2 targeted inhibitor Lapatinib in the treatment of refractory Cushing's disease | A single center clinical study of EGFR/HER2 targeted inhibitor Lapatinib in the treatment of refractory Cushing's disease | Pituitary ACTH-secreting adenoma | Treatment group:lapatinib; | Peking Union Medical College Hospital | Not Recruiting | 18 | 75 | Both | Treatment group:30; | Post-market | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT03111810 | May 25, 2017 | 16 December 2017 | Targeting Iatrogenic Cushing's Syndrome With 11ß-hydroxysteroid Dehydrogenase Type 1 Inhibition | Targeting Iatrogenic Cushing's Syndrome With 11ß-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) | Iatrogenic Cushing's Disease | Drug: AZD4017 and prednisolone;Drug: Placebo Oral Tablet and prednisolone | University of Oxford | AstraZeneca | Recruiting | 18 Years | 60 Years | Male | 32 | Phase 2 | United Kingdom |
| 22 | NCT03145285 | April 18, 2017 | 16 December 2017 | Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma | Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma | Cushing Syndrome;Adrenocortical Carcinoma | Drug: Abiraterone Acetate | Azienda Ospedaliera Spedali Civili di Brescia | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;Niguarda Hospital;San Camillo Hospital, Rome;San Luigi Gonzaga Hospital | Not recruiting | 18 Years | N/A | All | 10 | Phase 2 | Italy |
| 23 | NCT03053271 | April 13, 2017 | 30 September 2019 | A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome | Cushing Syndrome | Drug: ATR-101;Drug: Placebo | Millendo Therapeutics US, Inc. | Not recruiting | 18 Years | 80 Years | All | 4 | Phase 2 | United States;United Kingdom | |
| 24 | EUCTR2016-003060-40-GB | 17/01/2017 | 8 May 2017 | Treating side effects of steroid medication | Targeting Iatrogenic Cushing’s Syndrome with 11ß-hydroxysteroid dehydrogenase type 1 Inhibition - TICSI version 0.6 | Adverse effects of prescribed glucocorticoid therapy MedDRA version: 19.0 Level: LLT Classification code 10068501 Term: Cushing's syndrome, steroid-induced System Organ Class: 100000004860 ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Product Name: AZD4017 Product Code: AZD4017 Pharmaceutical Form: Tablet INN or Proposed INN: no INN available CAS Number: 1024033-43-9 Current Sponsor code: TICSI Other descriptive name: AZD4017 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | University of Oxford, Clinical Trials and Research Governance | Authorised | Female: no Male: yes | 32 | Phase 2 | United Kingdom | |||
| 25 | NCT02697734 | October 3, 2016 | 30 September 2019 | Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease | A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease | Cushing's Disease | Drug: osilodrostat;Drug: osilodrostat Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | 75 Years | All | 73 | Phase 3 | United States;Belgium;Brazil;Canada;China;Costa Rica;Greece;Poland;Portugal;Russian Federation;Spain;Switzerland;Thailand;Turkey | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | EUCTR2016-000899-23-GB | 16/08/2016 | 28 February 2019 | Clinical trial to assess the safety and effectiveness of a study drug called CORT125134 in the treatment of Cushing's syndrome | Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing’s Syndrome | Endogenous Cushing’s Syndrome MedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860 ;Therapeutic area: Body processes [G] - Physiological processes [G07] | Product Code: CORT125134 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Relacorilant CAS Number: 1496510-51-0 Current Sponsor code: CORT125134 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- | Corcept Therapeutics Incorporated | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United States;Hungary;Netherlands;United Kingdom | |||
| 27 | NCT02611258 | July 2016 | 5 February 2018 | Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs | Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in Cushing's Syndrome | Cushing's Syndrome Cardiomyopathy | Drug: Tadalafil | Andrea M. Isidori | Recruiting | 18 Years | 75 Years | All | 18 | Phase 2 | Italy | |
| 28 | NCT02804750 | June 2016 | 22 October 2019 | Study to Evaluate CORT125134 in Participants With Cushing's Syndrome | Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome | Cushing's Syndrome | Drug: CORT125134 | Corcept Therapeutics | Not recruiting | 18 Years | 80 Years | All | 35 | Phase 2 | United States;Hungary;Italy;Netherlands;United Kingdom | |
| 29 | EUCTR2014-004092-23-ES | 29/04/2016 | 13 June 2016 | Placebo-controlled study of the safety and efficacy of osilodrostat in patients with Cushing's Disease | A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing?s disease - LINC-4 | Cushing's disease MedDRA version: 18.1 Level: LLT Classification code 10011651 Term: Cushing's disease System Organ Class: 100000004860 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: osilodrostat 1mg Product Code: LCI699 Pharmaceutical Form: Tablet INN or Proposed INN: osilodrostat Current Sponsor code: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: osilodrostat 5mg Product Code: LCI699 Pharmaceutical Form: Tablet INN or Proposed INN: osilodrostat Current Sponsor code: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: osilodrostat 10mg Product Code: LCI699 Pharmaceutical Form: Tablet INN or Proposed INN: osilodrostat Current Sponsor code: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: osilodrostat 20mg Product Code: LCI699 Pharmaceutical Form: Tablet INN or Proposed INN: osilodrostat Current Sponsor code: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Novartis Farmacéutica, S.A. | Authorised | Female: yes Male: yes | 69 | Phase 3 | United States;Greece;Poland;Brazil;Belgium;Thailand;Spain;Turkey;Denmark;Russian Federation;Switzerland | |||
| 30 | JPRN-UMIN000018891 | 2015/10/01 | 2 April 2019 | The usefulness of DDAVP test and GHRP-2 test in patients with Cushing's disease | Cushing's disease | administration of DDAVP or GHRP-2 | Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine | Recruiting | 15years-old | Not applicable | Male and Female | 15 | Not selected | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT02468193 | September 24, 2015 | 9 September 2019 | Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome | A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease | Cushing's Syndrome;Ectopic Corticotropin Syndrome;Adrenal Adenoma;Adrenal Carcinoma;AIMAH;PPNAD | Drug: Osilodrostat | Novartis Pharmaceuticals | Not recruiting | 18 Years | 85 Years | All | 9 | Phase 2 | Japan | |
| 32 | NCT02484755 | June 2015 | 3 August 2015 | Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease | Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease | Cushing's Disease;Corticotrophin Adenoma | Drug: Gefitinib | Huashan Hospital | Recruiting | 18 Years | 70 Years | Both | 6 | Phase 2 | China | |
| 33 | NCT02297945 | April 2015 | 28 October 2019 | Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome | Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks | Cushing's Syndrome | Drug: metyrapone | HRA Pharma | Not recruiting | 18 Years | N/A | All | 50 | Phase 3 | Belgium;Germany;Hungary;Italy;Poland;Romania;Spain;Turkey | |
| 34 | EUCTR2014-000162-22-IT | 19/03/2015 | 17 August 2015 | Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment period | Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT | Treatment of Cushing’s syndrome MedDRA version: 17.1 Level: PT Classification code 10011652 Term: Cushing's syndrome System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Metopirone 250 mg capsules/Cormeto Product Name: metyrapone Pharmaceutical Form: Capsule INN or Proposed INN: METYRAPONE CAS Number: 54-36-4 Concentration unit: mg milligram(s) Concentration number: 250- | Laboratoire HRA Pharma | Authorised | Female: yes Male: yes | 70 | United States;Poland;Belgium;Spain;Germany;Switzerland;Italy;Sweden | ||||
| 35 | NCT02180217 | October 6, 2014 | 28 October 2019 | Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease | Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease | Cushing's Disease | Drug: LCI699;Drug: LCI699 matching placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | 75 Years | All | 137 | Phase 3 | United States;Argentina;Austria;Bulgaria;Canada;China;Colombia;France;Germany;India;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Thailand;Turkey;United Kingdom;Australia | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | EUCTR2012-002916-16-DE | 19/08/2014 | 28 February 2019 | Study of management of pasireotide-induced hyperglycemia in adult patients with Cushing’s disease or acromegaly | A multi-center, randomized, open-label, Phase IV study to investigate the management of pasireotide-induced hyperglycemia with incretin based therapy or insulin in adult patients with Cushing’s disease or acromegaly. | Cushing's disease and acromegaly MedDRA version: 19.0 Level: LLT Classification code 10011651 Term: Cushing's disease System Organ Class: 100000004860 MedDRA version: 19.0 Level: LLT Classification code 10000600 Term: Acromegaly and gigantism System Organ Class: 100000004860 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Signifor Product Name: pasireotide Product Code: SOM230, 300micrograms Pharmaceutical Form: Solution for injection INN or Proposed INN: PASIREOTIDE Current Sponsor code: SOM230 Other descriptive name: PASIREOTIDE DIASPARTATE Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 300- Trade Name: Signifor Product Name: pasireotide Product Code: SOM230, 600 micrograms Pharmaceutical Form: Solution for injection INN or Proposed INN: PASIREOTIDE Current Sponsor code: SOM230 Other descriptive name: PASIREOTIDE DIASPARTATE Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 600- Trade Name: Signifor Product Name: pasireotide Product Code: SOM230, 900 micrograms Pharmaceutical Form: Solution for injection INN or Proposed INN: PASIREOTIDE Current Sponsor code: SOM230 Other descriptive name: PASIREOTIDE DIASPARTATE Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 900- Product Name: pasireotide LAR Product Code: SOM230 LAR, 20 mg Pharmaceutical Form: Powder and solvent for suspension for injection INN or Proposed INN: PASIREOTIDE Current Sponsor code: SOM230 Other descriptive name: PASIREOTIDE PAMOATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 133 | Phase 4 | United States;Belgium;Poland;Turkey;Denmark;Russian Federation;Germany;China | |||
| 37 | EUCTR2013-004766-34-IT | 01/08/2014 | 9 March 2015 | Safety and efficacy of LCI699 for the treatment of patients with Cushing's disease | A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing’s disease | Cushing's disease;Therapeutic area: Diseases [C] - Cancer [C04] | Product Name: NA Product Code: LCI699 Pharmaceutical Form: Tablet INN or Proposed INN: NA CAS Number: 1315449-72-9 Current Sponsor code: LCI699 Other descriptive name: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: NA Product Code: LCI699 Pharmaceutical Form: Tablet INN or Proposed INN: NA CAS Number: 1315449-72-9 Current Sponsor code: LCI699 Other descriptive name: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: NA Product Code: LCI699 Pharmaceutical Form: Tablet INN or Proposed INN: NA CAS Number: 1315449-72-9 Current Sponsor code: LCI699 Other descriptive name: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: NA Product Code: LCI699 Pharmaceutical Form: Tablet INN or Proposed INN: NA CAS Number: 1315449-72-9 Current Sponsor code: LCI699 Other descriptive name: LCI699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | NOVARTIS FARMA S.p.A. | Authorised | Female: yes Male: yes | 132 | Phase 3 | United States;Taiwan;Slovakia;Spain;Thailand;Turkey;Austria;Russian Federation;Colombia;Italy;United Kingdom;India;France;Canada;Argentina;Australia;Bulgaria;Netherlands;Germany;Japan;China;Korea, Republic of | |||
| 38 | NCT01838551 | August 2014 | 18 December 2018 | Treatment for Endogenous Cushing's Syndrome | An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome | Endogenous Cushing's Syndrome | Drug: COR-003 | Cortendo AB | Not recruiting | 18 Years | N/A | All | 90 | Phase 3 | United States;Belgium;Bulgaria;Canada;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Serbia;Spain;Turkey;Czech Republic;Georgia;Hungary;Sweden;Switzerland;United Kingdom | |
| 39 | NCT02060383 | May 23, 2014 | 21 January 2019 | Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly | A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly | Cushing's Disease;Acromegaly | Drug: Pasireotide s.c.;Drug: Sitagliptin;Drug: Liraglutide;Drug: Insulin;Drug: Pasireotide LAR;Drug: Metformin | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 247 | Phase 4 | United States;Belgium;Brazil;China;Denmark;Germany;India;Peru;Poland;Russian Federation;Thailand;Turkey | |
| 40 | NCT02160730 | May 2014 | 19 November 2018 | Treatment of Cushing's Disease With R-roscovitine | Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine | Cushings Disease | Drug: R-roscovitine | Shlomo Melmed, MD | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 18 Years | N/A | All | 7 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT01915303 | March 6, 2014 | 24 June 2019 | Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease | A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease | Cushing's Disease | Drug: Pasireotide with or without cabergoline | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 64 | Phase 2 | United States;Argentina;Australia;Belgium;Brazil;Bulgaria;Colombia;France;Germany;Greece;Hungary;India;Italy;Malaysia;Mexico;Netherlands;Spain;Turkey;Venezuela | |
| 42 | NCT02019706 | November 26, 2013 | 28 October 2019 | Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome | Evaluation of 68Ga -DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome | ACTH;Cushing's Syndrome | Drug: DOTATATE PET-CT;Drug: F-DOPA PET CT;Drug: OCTREOTIDE;Radiation: CT Scan;Device: MRI | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | 18 Years | 90 Years | All | 80 | Phase 1/Phase 2 | United States | |
| 43 | EUCTR2013-002170-49-DE | 19/11/2013 | 30 April 2019 | A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease | A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease | Cushing's disease MedDRA version: 19.0 Level: LLT Classification code 10011651 Term: Cushing's disease System Organ Class: 100000004860 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Signifor Product Name: pasireotide Product Code: SOM230 Pharmaceutical Form: Solution for injection INN or Proposed INN: PASIREOTIDE DIASPARTATE CAS Number: 396091-77-3 Current Sponsor code: SOM230 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.3- Trade Name: Signifor Product Name: pasireotide Product Code: SOM230 Pharmaceutical Form: Solution for injection INN or Proposed INN: PASIREOTIDE DIASPARTATE CAS Number: 396091-77-3 Current Sponsor code: SOM230 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Trade Name: Signifor Product Name: pasireotide Product Code: SOM230 Pharmaceutical Form: Solution for injection INN or Proposed INN: PASIREOTIDE DIASPARTATE CAS Number: 396091-77-3 Current Sponsor code: SOM230 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.9- Trade Name: Dostinex Product Name: Cabergoline Pharmaceutical Form: Tablet Other descriptive name: CABERGOLINE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,5- | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 64 | Phase 2 | United States;Venezuela, Bolivarian Republic of;Greece;Spain;Turkey;Colombia;Italy;India;France;Hungary;Mexico;Argentina;Malaysia;Belgium;Brazil;Australia;Bulgaria;Netherlands;Germany | |||
| 44 | EUCTR2013-002063-26-IT | 08/09/2013 | 7 April 2015 | A trial with Metyrapone in Cushing's syndrome | A prospective open-label Phase 2 study of METYRAPONE as a preoperative treatment in patients with ACTH-independent Cushing’s syndrome due to adrenal adenoma. - METYX01 | Cushing's syndrome;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Matyrapone Product Name: Metyrapone Product Code: Metyrapone Pharmaceutical Form: Capsule, soft | S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi Orbassano | Authorised | Female: yes Male: yes | 15 | Phase 2 | Italy | |||
| 45 | NCT01925092 | August 2013 | 19 February 2015 | Mifepristone in Children With Refractory Cushing's Disease | An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease | Cushing's Disease | Drug: mifepristone | Corcept Therapeutics | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Not recruiting | 6 Years | 17 Years | Both | 0 | Phase 3 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT01794793 | June 10, 2013 | 7 October 2019 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment | Cushing's Disease;Acromegaly;Neuroendocrine Tumors;Pituitary Tumors;Ectopic ACTH Secreting (EAS) Tumors;Dumping Syndrome;Prostate Cancer;Melanoma Negative for bRAF;Melanoma Negative for nRAS | Drug: Pasireotide;Drug: Cabergoline | Novartis Pharmaceuticals | Recruiting | 18 Years | N/A | All | 500 | Phase 4 | United States;Argentina;Belgium;Brazil;Bulgaria;Canada;China;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;Thailand;Turkey | |
| 47 | NCT03080181 | May 2013 | 16 December 2017 | Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment | Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters | Cushing Disease | Drug: Pasireotide 0.6 MG/ML | University of Palermo | Not recruiting | 18 Years | N/A | All | 24 | Phase 4 | ||
| 48 | NCT02310269 | March 28, 2013 | 29 July 2019 | Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease | Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study) | Cushings Disease | Drug: SOM230 | Novartis Pharmaceuticals | Recruiting | 18 Years | N/A | All | 200 | Phase 4 | United States;Canada;Colombia;France;Germany;Israel;Italy;Lebanon;Netherlands;Romania;Sweden;United Kingdom;Denmark | |
| 49 | NCT02889224 | February 2012 | 22 October 2018 | In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man | In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man | Cushing's Syndrome | Other: Control;Other: Hydrocortisone;Procedure: Hypercortisolism;Other: Obese | University Hospital, Bordeaux | Not recruiting | 18 Years | N/A | All | 40 | N/A | France | |
| 50 | NCT01374906 | November 4, 2011 | 11 June 2018 | Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease | A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease | Cushing's Disease | Drug: pasireotide LAR;Drug: SOM230 LAR 30 mg;Drug: SOM230 LAR 10 mg | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 150 | Phase 3 | United States;Argentina;Belgium;Brazil;Canada;China;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Russian Federation;Spain;Thailand;Turkey;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | EUCTR2011-003264-77-NL | 31/10/2011 | 19 March 2012 | A study with ketoconazole and octreotide combination therapy for treatment of Cushing’s disease. | A prospective trial with ketoconazole and octreotide combination therapy for treatment of Cushing’s disease. - Octreotide and ketoconazole for Cushing's disease | Cushing's disease (which is caused by an ACTH producing pituitary adenoma) MedDRA version: 14.0 Level: LLT Classification code 10011651 Term: Cushing's disease System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Octreotide Product Name: Octreotide Product Code: RVG 18236 Pharmaceutical Form: Powder and solvent for solution for injection Trade Name: Ketoconazole Product Name: Ketoconazole Product Code: RVG 08938 Pharmaceutical Form: Tablet Trade Name: Cabergoline Product Name: Cabergoline Product Code: RVG 15375 Pharmaceutical Form: Tablet | Erasmus MC | Authorised | Female: yes Male: yes | Netherlands | |||||
| 52 | NCT01459237 | October 11, 2011 | 25 June 2018 | Effects of Hormone Stimulation on Brain Scans for Cushing s Disease | Prospective Evaluation of the Effect of Corticotropin-Releasing Hormone Stimulation on 18F-Fludeoxyglucose High-Resolution Positron-Emission Tomography in Cushing's Disease | Pituitary Neoplasm | Drug: Acthrel | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 8 Years | N/A | All | 30 | Early Phase 1 | United States | |
| 53 | EUCTR2010-024165-44-DE | 05/08/2011 | 5 February 2018 | An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease (Seascape) | An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease (Seascape) - Seascape | Cushing’s disease MedDRA version: 14.1 Level: LLT Classification code 10011651 Term: Cushing's disease System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Cancer [C04] | Trade Name: Signifor Product Name: Signifor Product Code: SOM230 300µg Pharmaceutical Form: Solution for injection INN or Proposed INN: pasireotide Current Sponsor code: SOM230B Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 300- Trade Name: Signifor Product Name: Signifor Product Code: SOM230 600µg Pharmaceutical Form: Solution for injection INN or Proposed INN: pasireotide Current Sponsor code: SOM230B Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 600- Trade Name: Signifor Product Name: Signifor Product Code: SOM230 900µg Pharmaceutical Form: Solution for injection INN or Proposed INN: pasireotide Current Sponsor code: SOM230B Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 900- | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | Czech Republic;Greece;Spain;Netherlands;Germany | |||
| 54 | NCT01331239 | March 23, 2011 | 22 October 2019 | Safety and Efficacy of LCI699 in Cushing's Disease Patients. | A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 Followed by a 12 - Week Treatment Period of LCI699 in Patients With Cushing's Disease | Cushing's Disease | Drug: LCI699 | Novartis Pharmaceuticals | Not recruiting | 18 Years | 75 Years | All | 33 | Phase 2 | United States;France;Italy;Japan | |
| 55 | NCT01371565 | November 2010 | 19 October 2017 | Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome | Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome | Cushing's Disease;Cushing's Syndrome | Drug: Mifepristone | Corcept Therapeutics | Not recruiting | 18 Years | N/A | All | 4 | Phase 3 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | EUCTR2008-005708-18-GB | 04/06/2010 | 19 March 2012 | Prevention of metabolic complications of glucocorticoid excess - Prevention of metabolic complications of glucocorticoid excess | Prevention of metabolic complications of glucocorticoid excess - Prevention of metabolic complications of glucocorticoid excess | Rheumatoid arthritis, SLE, Polymyalgia rheumatica, Disthyroid eye disease, Cushing's syndrome | Trade Name: Glucophage (metformin) Product Name: Metformin Pharmaceutical Form: Tablet | Queen Mary University of London | Authorised | Female: yes Male: yes | United Kingdom | |||||
| 57 | EUCTR2010-018720-12-SE | 22/04/2010 | 23 September 2013 | Behandling med kabergolin hos patienter med ACTH-beroende Cushing´s syndrom (treatment with cabergoline in patients with ACTH-dependent Cushing´s syndrome - Cushing and cabergoline | Behandling med kabergolin hos patienter med ACTH-beroende Cushing´s syndrom (treatment with cabergoline in patients with ACTH-dependent Cushing´s syndrome - Cushing and cabergoline | A) Men and women aged 18 to 75 years with hypercortisolism due to ACTH-dependent Cushing's syndrome will be treated in the period between diagnosis and planned surgery or radiation therapy. B) Men and women aged 18 to 75 years due to ACTH-dependent Cushing's syndrome who have persistent hypercortisolism post-surgery or post-radiotherapy. | Product Name: cabergoline Pharmaceutical Form: Tablet | Swedish Pituitary Study group | Authorised | Female: yes Male: yes | 20 | Sweden | ||||
| 58 | JPRN-UMIN000002925 | 2009/12/01 | 22 July 2019 | Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension. | Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension. - A pilot study to compare efficacy of Eplerenone monotherapy with Valsartan monotherapy. | Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension. | 50mg of Eplerenone monotherapy once daily for 6 weeks on subclinical Cushing's syndrome 80mg of Valsartan monotherapy once daily for 6 weeks on subclinical Cushing's syndrome 50mg of Eplerenone monotherapy once daily for 6 weeks on non-functioning adrenocortical adenoma 80mg of Valsartan monotherapy once daily for 6 weeks on non-functioning adrenocortical adenoma | Hiroshima University Hospital Department of Endocrinology and Diabetes mellitus | Not Recruiting | 20years-old | Not applicable | Male and Female | 80 | Not selected | Japan | |
| 59 | EUCTR2009-010918-30-IE | 11/08/2009 | 19 March 2012 | Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism. | Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism. | 20 patients with hypopituitarism including growth hormone deficiency will be evaluated both on growth hormone replacement and when they have been off it for a 2 month period. They will have been prescribed growth hormone replacement in the form of Genotropin/Genotropin Miniquick/Norditropin prior to inclusion in this study as part of their routine clinical care. MedDRA version: 9.1 Level: LLT Classification code 10021067 Term: Hypopituitarism MedDRA version: 9.1 Level: LLT Classification code 10033662 Term: Panhypopituitarism MedDRA version: 9.1 Level: LLT Classification code 10056438 Term: Growth hormone deficiency MedDRA version: 9.1 Level: LLT Classification code 10011318 Term: Craniopharyngioma MedDRA version: 9.1 Level: LLT Classification code 10036832 Term: Prolactinoma MedDRA version: 9.1 Level: LLT Classification code 10011651 Term: Cushing's disease MedDRA version: 9.1 Level: LLT Classification code 10035104 Term: Pituitary tumour MedDRA version: 9.1 Level: LLT Classification code 10061538 Term: Pituitary tumour benign | Trade Name: Genotropin 5.3mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 5.3- Trade Name: Genotropin 12mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 12- Trade Name: Genotropin Miniquick 0.2mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.2- Trade Name: Genotropin Miniquick 0.4mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.4- Trade Name: Genotropin Miniquick 0.6mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Trade Name: Genotropin Miniquick 0.8mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.8- Trade Name: Genotropin Miniquick 1.0mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- Trade Name: Genotropin Miniquick 1.2mg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: SOMATROPIN CAS Number: 12629015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.2- | Amar Agha, Beaumont Hospital | Authorised | Female: yes Male: yes | 20 | Ireland | ||||
| 60 | NCT00936741 | July 2009 | 19 October 2017 | An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome | An Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome | Cushing's Syndrome | Drug: mifepristone | Corcept Therapeutics | Not recruiting | 18 Years | N/A | All | 30 | Phase 3 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | EUCTR2007-007604-15-GB | 03/03/2009 | 19 March 2012 | A Pilot Study of the Effect of Glucocorticoid Receptor Antagonism in Patients with Sub-Clinical Cushing's Syndrome - Glucocorticoid Receptor Antagonism in Sub-Clinical Cushings | A Pilot Study of the Effect of Glucocorticoid Receptor Antagonism in Patients with Sub-Clinical Cushing's Syndrome - Glucocorticoid Receptor Antagonism in Sub-Clinical Cushings | Sub Clinical Cushing's Syndrome MedDRA version: 9.1 Level: PT Classification code 10011652 Term: Cushing's syndrome | Trade Name: mifedren Product Name: HRA052015 (mifepristone) Product Code: HRA052015 Pharmaceutical Form: Tablet INN or Proposed INN: MIFEPRISTONE CAS Number: 84371653 Current Sponsor code: HRA052015 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- | Sheffield Teaching Hospitals NHS Foundation Trust | Authorised | Female: yes Male: yes | 6 | United Kingdom | ||||
| 62 | NCT00796783 | February 2009 | 19 February 2015 | A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia | A Study to Confirm the Presence of Recurrent or Persistent Cushing's Syndrome in Patients With Clinical Signs or Symptoms of Hypercortisolemia Who Have Been Treated for Cushing's Disease | Cushing's Syndrome | Drug: Cushing's syndrome confirmation | Corcept Therapeutics | Not recruiting | 18 Years | N/A | Both | 2 | N/A | United States | |
| 63 | NCT00721201 | November 2008 | 19 February 2015 | Glucocorticoid Receptor Antagonism in Subclinical Cushings | A Pilot Study of the Effect of a Glucocorticoid Receptor Antagonist in Patients With Subclinical Cushings | Subclinical Cushing's | Drug: Mifepristone | Sheffield Teaching Hospitals NHS Foundation Trust | Not recruiting | 18 Years | N/A | Both | 6 | Phase 1/Phase 2 | United Kingdom | |
| 64 | NCT00845351 | November 2008 | 19 February 2015 | Preoperative Bexarotene Treatment for Cushing's Disease | Preoperative Bexarotene Treatment for Cushing's Disease | Cushing's Disease | Drug: Bexarotene | University of Virginia | Recruiting | 18 Years | 65 Years | Both | 6 | Phase 1/Phase 2 | United States | |
| 65 | EUCTR2008-006379-65-IT | 27/10/2008 | 3 April 2012 | Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease - Retinoic acid in Cushing`s disease | Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease - Retinoic acid in Cushing`s disease | sperimentation only in patients | Pharmaceutical Form: Capsule, hard INN or Proposed INN: Tretinoin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | ISTITUTO AUXOLOGICO ITALIANO | Authorised | Female: yes Male: yes | Italy | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | EUCTR2008-002280-14-FR | 18/07/2008 | 19 March 2012 | Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, randomized, open-label, two-period,cross-over trial | Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, randomized, open-label, two-period,cross-over trial | The Active substance of Osteopor is Ossein Hydroxyapatite. Treatment of processes characterized by decalcification: osteoporosis, Cushing syndrome, thyrotoxicosis. MedDRA version: 9.1 Level: LLT Classification code 10006956 Term: Calcium deficiency | Trade Name: OSTEOPOR Product Name: OSTEOPOR Product Code: L0006CP03A Pharmaceutical Form: Tablet INN or Proposed INN: ossein hydroxyapatite Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 830- Trade Name: OROCAL Product Name: OROCAL Pharmaceutical Form: Tablet INN or Proposed INN: calcium carbonate CAS Number: 471341 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- | Pierre Fabre Médicament | Authorised | Female: yes Male: no | France | |||||
| 67 | NCT00569582 | December 2007 | 19 October 2017 | A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome | An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome | Cushing's Syndrome | Drug: mifepristone | Corcept Therapeutics | Not recruiting | 18 Years | N/A | All | 50 | Phase 3 | United States | |
| 68 | NCT00889525 | November 2007 | 19 February 2015 | Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor | Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor | Cushing's Disease;Corticotroph Adenoma | Drug: Cabergoline | Seth Gordhandas Sunderdas Medical College | Not recruiting | 12 Years | N/A | Both | Phase 3 | India | ||
| 69 | EUCTR2006-004080-55-NL | 26/04/2007 | 19 March 2012 | Stepwise Medical Treatment of Cushing’s Disease: a prospective open label multi-center trial with SOM230 mono- and combination therapy with dopamine agonists and ketoconazole - Stepwise Medical Treatment of Cushing's Disease | Stepwise Medical Treatment of Cushing’s Disease: a prospective open label multi-center trial with SOM230 mono- and combination therapy with dopamine agonists and ketoconazole - Stepwise Medical Treatment of Cushing's Disease | The medical condition to be investigated is Cushing's disease which is caused by an ACTH producing pituitary adenoma MedDRA version: 8.1 Level: LLT Classification code 10011651 Term: Cushing's disease | Product Name: SOM230 Product Code: SOM230B Pharmaceutical Form: Solution for injection INN or Proposed INN: pasireotide Concentration unit: µg microgram(s) Concentration type: equal Trade Name: Dostinex Product Name: Dostinex Pharmaceutical Form: Tablet INN or Proposed INN: CABERGOLINE CAS Number: 81409907 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Nizoral Product Name: Ketoconazole Pharmaceutical Form: Tablet INN or Proposed INN: KETOCONAZOLE CAS Number: 65277421 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- | Erasmus MC | Authorised | Female: yes Male: yes | Netherlands | |||||
| 70 | NCT00612066 | April 2007 | 19 October 2017 | Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) | An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease | Cushing's Disease | Drug: rosiglitazone maleate | Jonsson Comprehensive Cancer Center | National Cancer Institute (NCI) | Not recruiting | 18 Years | 65 Years | All | 2 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | EUCTR2006-004111-22-DK | 05/01/2007 | 16 March 2015 | A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s disease | A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s disease | Cushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to produce excess cortisol, leading to the subsequent development of the clinical signs and symptoms of hypercortisolism. Cushing's disease is associated with severe morbidity and premature mortality and most commonly affects adults aged 20-50, primarily females MedDRA version: 8.1 Level: LLT Classification code 10011651 Term: Cushing's disease | Product Name: pasireotide Product Code: SOM230B Pharmaceutical Form: Solution for injection INN or Proposed INN: pasireotide CAS Number: 396091-77-3 Current Sponsor code: SOM230 (di-aspartate) Other descriptive name: Cyclo((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe) di-aspartate Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 300-900 | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 146 | Portugal;Hungary;Greece;Finland;Belgium;Denmark;Germany;United Kingdom;Italy | ||||
| 72 | EUCTR2006-004679-36-FR | 13/12/2006 | 22 December 2015 | Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS | Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS | Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. MedDRA version: 8.1 Level: LLT Classification code 10014155 Term: Ectopic corticotrophin syndrome | Product Code: HRA052015 Pharmaceutical Form: Tablet INN or Proposed INN: mifepristone CAS Number: 84371-65-3 Other descriptive name: 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- | Laboratoire HRA Pharma | Not Recruiting | Female: yes Male: yes | 22 | France;Netherlands;Germany;Italy | ||||
| 73 | EUCTR2006-005218-11-IT | 15/09/2006 | 26 June 2012 | EFFECTIVENESS AND TOLERABILITY OF TREATMENT WITH CABERGOLINE IN PATIENTS WITH CUSHING S SYNDROME - CABERGOLINE IN CUSHING S SYNDROME | EFFECTIVENESS AND TOLERABILITY OF TREATMENT WITH CABERGOLINE IN PATIENTS WITH CUSHING S SYNDROME - CABERGOLINE IN CUSHING S SYNDROME | Cushing syndrome MedDRA version: 9.1 Level: LLT Classification code 10011652 Term: Cushing's syndrome | Trade Name: DOSTINEX Pharmaceutical Form: Tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .5- Trade Name: NIZORAL Pharmaceutical Form: Tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- | ASSOCIAZIONE ITALIANA ENDOCRINOLOGIA-METABOLISMO-IPOFISI | Authorised | Female: yes Male: yes | Italy | |||||
| 74 | EUCTR2004-002407-32-IT | 21/10/2004 | 14 October 2013 | \\ | Extension to a multicenter, open label study to assess the safety and efficacy of 600 micrograms SOM230, administered subcutaneously, b.i.d. in patients with Cushing's disease | Treatment of Cushing's disease MedDRA version: 14.1 Level: PT Classification code 10035109 Term: Pituitary-dependent Cushing's syndrome System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: NA Product Code: SOM230B Pharmaceutical Form: Solution for injection INN or Proposed INN: PASIREOTIDE CAS Number: 396091-77-3 Current Sponsor code: SOM230B Concentration unit: µg microgram(s) Concentration number: 900- | NOVARTIS FARMA | Not Recruiting | Female: yes Male: yes | 26 | United Kingdom;Italy | ||||
| 75 | NCT00088608 | April 2004 | 14 November 2016 | A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease | A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease | Cushing's Syndrome | Drug: SOM230 s.c. | Novartis Pharmaceuticals | Not recruiting | 18 Years | 80 Years | Both | 26 | Phase 2 | United States;France;Italy;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | NCT00001849 | February 26, 1999 | 20 May 2019 | New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome | New Imaging Modalities in the Evaluation of Patients With Ectopic Cushing's Syndrome | Cushing Syndrome;Endocrine Disease | Drug: Pentetreotide;Drug: 18F-DOPA | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Not recruiting | 18 Years | 90 Years | All | 98 | Phase 1/Phase 2 | United States | |
| 77 | NCT00001180 | March 1982 | 19 February 2015 | Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency | Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency | Adrenal Gland Hyperfunction;Adrenal Gland Hypofunction;Cushing's Syndrome;Healthy | Drug: Ovine Corticotropin-Releasing Hormone (oCRH) | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Not recruiting | N/A | N/A | Both | 2250 | N/A | United States |